604 Results for "

Allosteric Inhibitors

" in MedChemExpress (MCE) Product Catalog:
Products (604)

604 Results for "Allosteric Inhibitors" in MCE Product Catalog:

1441
1441 Publications Verification
Cat. No.: HY-10219
CAS No.: 53123-88-9
Purity:  99.94%
Synonyms: Sirolimus; AY-22989; NSC 226080
Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin is a molecular glue that binds FKBP12 and mTOR proteins together, thereby inhibiting mTOR kinase activity. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .
loading...
    loading...
111
111 Cited Publications
Cat. No.: HY-10046
CAS No.: 110078-46-1
Purity:  99.90%
Synonyms: AMD 3100; JM3100; SID791
Target:  

CXCR HIV

Plerixafor (AMD 3100) is a selective CXCR4 antagonist with an IC50 of 44 nM. Plerixafor, an immunostimulant and a hematopoietic stem cell (HSC) mobilizer, is an allosteric agonist of CXCR7. Plerixafor inhibits HIV-1 and HIV-2 replication with an EC50 of 1-10 nM .
loading...
    loading...
76
76 Cited Publications
Cat. No.: HY-100388
CAS No.: 1801747-42-1
Purity:  99.81%
Target:  

SHP2 Phosphatase

Research Areas:  

Cancer

SHP099 is an allosteric SHP2 inhibitor, with IC50s of 0.690, 1.241, 0.416, 1.968, 2.896 μM for SHP2, SHP2 D61Y, SHP2E69K, SHP2 A72V, SHP2 E76K. SHP099 inhibits cancer cell growth, such as MV4-11 and TF-1 cell (IC50: 0.32 and 1.73 μM). SHP099 inhibits RAS-ERK signaling and inhibits tumor growth .
loading...
    loading...
65
65 Cited Publications
Cat. No.: HY-10355
CAS No.: 612847-09-3
Purity:  98.36%
Synonyms: AKTi-1/2
Target:  

Akt Apoptosis

Research Areas:  

Metabolic Disease Cancer

AKT inhibitor VIII (AKTi-1/2) is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and Akt3 activity with IC50s of 58 nM, 210 nM, and 2119 nM, respectively.
loading...
    loading...
63
63 Cited Publications
Cat. No.: HY-12683
CAS No.: 314045-39-1
Purity:  98.07%
Target:  

Glutaminase

Research Areas:  

Cancer

BPTES is an allosteric and selective glutaminase inhibitor with an IC50 of 0.16 μM.
loading...
    loading...
63
63 Cited Publications
Cat. No.: HY-15251
CAS No.: 266359-83-5
Purity:  99.99%
Synonyms: Repertaxin; DF 1681Y
Target:  

CXCR

Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively.
loading...
    loading...
63
63 Cited Publications
Cat. No.: HY-15252
CAS No.: 266359-93-7
Purity:  99.87%
Synonyms: Repertaxin L-lysine salt
Target:  

CXCR

Reparixin L-lysine salt is an allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation.
loading...
    loading...
52
52 Cited Publications
Cat. No.: HY-141520
CAS No.: 2603528-97-6
Purity:  99.75%
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

ART558 is a potent, selective and allosteric DNA polymerase theta (Polθ) inhibitor (IC50=7.9 nM). ART558 elicits BRCA-gene synthetic lethality and DNA damage. ART558 can be used for the research of cancer, such as breast cancer .
loading...
    loading...
50
50 Cited Publications
Cat. No.: HY-15310
CAS No.: 70288-86-7
Purity:  98.28%
Synonyms: MK-933; CD-5024; K-237
Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X4 and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .
loading...
    loading...
41
41 Cited Publications
Cat. No.: HY-10299
CAS No.: 1088965-37-0
Purity:  99.48%
Target:  

Kinesin Apoptosis

Research Areas:  

Cancer

GSK-923295 is a special, allosteric inhibitor of centromere-associated protein-E (CENP-E) kinesin motor ATPase activity, with Ki of 3.2±0.2 nM and 1.6± 0.1 nM for human and canine, respectively.
loading...
    loading...
40
40 Cited Publications
Cat. No.: HY-119374
CAS No.: 2270879-17-7
Purity:  99.72%
Target:  

SWI/SNF Complex

Research Areas:  

Cancer

BRM/BRG1 ATP Inhibitor-1 (compound 14) is an orally active allosteric dual brahma homolog (BRM)/SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily A member 2 (SMARCA2) and brahma related gene 1 (BRG1)/SMARCA4 ATPase activity inhibitor, both IC50s are below 0.005 µM. BRM/BRG1 ATP Inhibitor-1 has anticancer activity .
loading...
    loading...
38
38 Cited Publications
Cat. No.: HY-10518
CAS No.: 547757-23-3
Purity:  99.90%
Target:  

IKK

Research Areas:  

Cancer

BMS-345541 hydrochloride is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC50=0.3 μM, IKK-1 IC50=4 μM). BMS-345541 binds at an allosteric site of IKK.
loading...
    loading...
38
38 Cited Publications
Cat. No.: HY-10519
CAS No.: 445430-58-0
Purity:  99.86%
Target:  

IKK

Research Areas:  

Cancer

BMS-345541 is a selective inhibitor of the catalytic subunits of IKK (IKK-2 IC50=0.3 μM, IKK-1 IC50=4 μM). BMS-345541 binds at an allosteric site of IKK.
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-12755
CAS No.: 71203-35-5
Purity:  99.96%
Synonyms: CID-2950007
Target:  

Ras Apoptosis

Research Areas:  

Cancer

ML141 (CID-2950007) is a potent, allosteric, selective and reversible non-competitive inhibitor of Cdc42 GTPase. ML141 inhibits Cdc42 wild type and Cdc42 Q61L mutant with EC50s of 2.1 and 2.6 μM, respectively. ML141 shows low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 do not show cytotoxicity in multiple cell lines .
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-117287
CAS No.: 1609392-27-9
Purity:  99.87%
Synonyms: BMS-986165
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-15713
CAS No.: 1418013-75-8
Purity:  99.92%
Target:  

p97

Research Areas:  

Cancer

NMS-873 is a potent, selective allosteric VCP/p97 inhibitor with an IC50 value of 30 nM.
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-19719
CAS No.: 1313881-70-7
Synonyms: ARQ-092
Target:  

Akt Parasite

Research Areas:  

Infection Cancer

Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib is effective against Leishmania .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-19719A
CAS No.: 1313883-00-9
Synonyms: ARQ-092 hydrochloride
Target:  

Akt Parasite

Research Areas:  

Infection Cancer

Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib hydrochloride is effective against Leishmania .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-104010
CAS No.: 1492952-76-7
Purity:  99.61%
Synonyms: ABL001
Target:  

Bcr-Abl

Research Areas:  

Cancer

Asciminib (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM .
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-104010A
CAS No.: 2119669-71-3
Purity:  99.84%
Synonyms: ABL001 hydrochloride
Target:  

Bcr-Abl

Research Areas:  

Cancer

Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM .
loading...
    loading...